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Barrett’s oesophagus (BE) is the precursor lesion to adenocarcinoma of the oesophagus. Understanding of the molecular alterations
in this multistage process may contribute to improved diagnosis and treatment. Secreted protein acidic and rich in cysteine (SPARC)
is a matricellular protein that modulates cell adhesion and growth. Alterations in SPARC expression have been observed in a variety
of solid tumours. The aim of this study was to assess the prevalence and timing of SPARC mRNA expression in Barrett’s multistage
disease and to investigate the impact of SPARC alterations on the development and progression of this disease. SPARC mRNA
expression was measured using a quantitative real-time RT–PCR method in 108 specimens from 19 patients with BE without
carcinoma, 20 patients with Barrett’s-associated adenocarcinoma (EA), and a control group (CG) of 10 patients without evidence of
gastro-oesophageal reflux disease. The median SPARC mRNA expression was significantly upregulated in BE tissues compared to
paired normal oesophagus (NE) tissues for the BE group (P¼0.004) and for the EA group (Po0.001). The SPARC mRNA
expression was significantly higher in adenocarcinoma of the oesophagus compared to matching NE tissue and compared to Barrett’s
tissues in the EA group (Po0.001). Furthermore, SPARC expression values were significantly different between metaplastic and
dysplastic Barrett’s tissues (P¼0.014). In histologically normal squamous oesophagus tissues obtained from carcinoma patients (EA
group), the SPARC mRNA expression was significantly higher compared to NE mucosa from the BE group and the CG group
(P¼0.03). These findings suggest that the upregulation of SPARC mRNA expression is an early event in the development and
progression of BE and EA, and that high SPARC expression may be a clinically useful biomarker for the detection of occult
adenocarcinoma, and that a widespread ‘field effect’ is present in the NE of patients with oesophageal adenocarcinoma.
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Barrett’s oesophagus (BE), the replacement of the normal stratified
squamous epithelium of the oesophagus by a metaplastic columnar
lining, is a premalignant condition caused by chronic gastro-
oesophageal reflux. This condition predisposes to the development
of oesophageal adenocarcinoma, the incidence of which has been
increasing rapidly in the United States and other Western
countries (Bollschweiler et al, 2001). Oesophageal adenocarcinoma
usually presents at an advanced stage and undergoes a rapidly fatal
course, with 5-year survival rates of approximately 25–30%
(Holscher et al, 1995). It is hoped that the identification of novel
biomarkers associated with each Barrett’s stage and with an
increased cancer risk will lead to earlier detection and improved
survival for patients with this disease.
Secreted protein acidic and rich in cysteine (SPARC), also
known as BM-40 and osteonectin, is a developmentally regulated
glycoprotein that is secreted into the extracellular matrix (ECM)
(Bradshaw and Sage, 2001). It functions as a counteradhesive
protein, modifying cell shape through the dissociation of focal
adhesion, and modulates cell–matrix interactions by binding to
the ECM (Bradshaw and Sage, 2001). Therefore, SPARC is thought
to influence several biological processes, including differentiation,
migration, and proliferation. Early in development, SPARC is
expressed in tissues undergoing remodelling (Mundlos et al, 1992)
and during vascular morphogenesis (Bradshaw and Sage, 2001). In
the adult, it becomes more restricted, but can be activated in
pathologic situations like wound healing (Reed et al, 1993).
However, recent evidence suggests that alterations in SPARC
expression are common in various human malignancies, including
melanoma (Ledda et al, 1997b), glioma (Schultz et al, 2002),
invasive meningioma (Rempel et al, 1999), hepatocellular carci-
noma (Le Bail et al, 1999), colon (Porte et al, 1995), breast (Gilles
et al, 1998), and prostate (Thomas et al, 2000) cancers. To date,
however, there are no detailed studies on SPARC expression in BE
and Barrett’s-associated adenocarcinoma (EA) of the oesophagus.
The aim of the underlying study was to analyse SPARC mRNA
expression in the development and progression of BE and EA, and
to determine the potential of SPARC mRNA quantitation in the
clinical management of this disease.
MATERIAL AND METHODS
Tissue samples for RT–PCR
A total of 108 tissue samples obtained at endoscopy and operation
from 19 patients with BE without adenocarcinoma (BE group), 20 Revised 1 July 2003; accepted 31 July 2003
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ypatients with EA (EA group), and 10 patients with no symptomatic,
endoscopic, or histopathologic evidence of BE or chronic gastro-
oesophageal reflux disease (control group, CG) were collected and
immediately frozen in liquid nitrogen. There were 31 men and 18
women, with a median age of 60.1 years (range 24–76 years).
Endoscopic biopsies were obtained according to a protocol that
required biopsy at 2cm intervals from each quadrant (anterior,
posterior, right, and left lateral positions) of the visible length of
Barrett’s mucosa and an additional biopsy from the normal
appearing squamous mucosa of the oesophagus. Normal oesopha-
gus (NE) biopsies were taken at least 4cm proximal to the
macroscopically abnormal epithelium. Part of the specimen or an
adjacent specimen was fixed in formalin and embedded in paraffin
for histopathological examination.
Specimens were classified as intestinal metaplasia (IM) if IM,
but no dysplasia or cancer was present. Specimens were classified
as dysplastic if either low-grade dysplasia (LGD) or high-grade
dysplasia (HGD) was present. Dysplastic tissues were not divided
into LGD or HGD groups because areas of LGD and HGD were
commonly present in the same specimen. Using these criteria, the
following tissues were analysed for SPARC mRNA expression:
Barrett’s IM (n¼16), Barrett’s dysplasia (n¼3), and matching
normal squamous tissue (n¼19) in the BE group, Barrett’s
adenocarcinoma of the oesophagus (n¼20), Barrett’s IM (n¼5),
Barrett’s dysplasia (15), and matching normal squamous oesopha-
gus tissues (n¼20) in the EA group, and normal squamous
oesophagus tissues (n¼10) in the CG, for a total of 108 specimens.
RNA extraction and cDNA synthesis
Total RNA was isolated by a single-step guanidinium isothiocya-
nate method using the QuickPrep
TMMicro mRNA Purification Kit
(Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA)
according to the manufacturer’s instructions, and cDNAs were
prepared as previously described (Chomczynski and Sacchi, 1987;
Lord et al, 2000).
PCR quantification of mRNA expression
Quantitation of SPARC cDNA and an internal reference cDNA (b-
actin) was carried out using a fluorescence detection method (ABI
PRISM 7700 Sequence Detection System, (TaqMan
s) Perkin-
Elmer (PE) Applied Biosystems, Foster City, CA, USA), as
described (Gibson et al, 1996; Heid et al, 1996; Lord et al, 2000).
The PCR reaction mixture consisted of 600nM of each primer,
200nM probe, 5U AmpliTaq Gold Polymerase, 200mM each dATP,
dCTP, dGTP, 400mM dUTP, 5.5mM MgCl2, and 1 Taqman Buffer
A containing a reference dye, to a final volume of 25ml (all reagents
Perkin-Elmer (PE) Applied Biosystems, Foster City, CA, USA).
Cycling conditions were 501C for 10s, 951C for 10min, followed by
46 cycles at 951C for 15s and 601C for 1min. The primers and
probes used are listed in Table 1. The set of SPARC primers was
designed to be RNA specific by spanning exons 8 and 9.
Statistical analysis
Taqman
s analyses yield values that are expressed as ratios
between two absolute measurements (gene of interest/internal
reference gene). SPARC expression levels in adenocarcinoma, BE,
and normal squamous oesophagus tissues were compared using
the Kruskal–Wallis test to identify significant differences in the
expressions among the histopathologic groups. The Kruskal–
Wallis test was also used to compare the three groups of NE
tissues. When the overall Kruskal–Wallis test (comparing three
groups) was significant at the 0.05 level, pairwise comparisons
were based on the Mann–Whitney test and the nominal P-value
was reported. The Wilcoxon signed-rank test was used for
comparison of paired tissues. Statistical significance (with two-
sided tests) was set at the 0.05 level.
RESULTS
SPARC mRNA expression was detectable by quantitative real-time
PCR (Taqman
s) in all 108 (100%) specimens. Analysed according
to histopathologic group, the median SPARC mRNA expression
was lowest in normal squamous oesophagus tissues (median 0.95,
range 0.14–16.50), intermediate in BE (median 3.89, range 0.09–
53.62), and highest in EA of the oesophagus (median 13.79, range
1.81–105.22; Po0.001, Kruskal–Wallis test).
Of the 19 (73.7%) patients, 14 with the maximum diagnosis of
BE (BE group, n¼19) had higher SPARC mRNA expression levels
in Barrett’s epithelium compared to matching normal squamous
oesophagus tissues. The median SPARC mRNA expression in
normal squamous oesophagus tissues was 1.07 (range 0.29–2.94)
and 2.99 in BE (range 0.09–7.19; P¼0.004, Wilcoxon’s test;
Figure 1; Table 2).
In the group of patients with EA (EA group, n¼20), 18 of 20
(90%) patients had higher SPARC mRNA expression levels in
cancer tissues compared to matching NE tissues. The median
Table 1 PCR primers and probes
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Figure 1 Box and whisker plots of relative SPARC mRNA expression
levels for NE and BE tissues from patients with the maximum diagnosis of
BE. The boxes show the 25th and 75th percentile (interquartile) ranges.
Median values are shown as a horizontal black bar within each box. The
whiskers show levels outside the 25th and 75th percentiles (P¼0.004).
Sparc in Barrett’s oesophagus
J Brabender et al
1509





























ySPARC mRNA expression was 1.79 (range 0.14–16.54) in NE, 6.91
(range 0.11–53.62) in Barrett’s epithelium, and 13.79 (range 1.81–
105.22) in EA (Po0.001, Kruskal–Wallis test). Table 2 and Figure 2
show that the median SPARC mRNA expression was significantly
higher in EA compared to matching NE tissues and Barrett’s
epithelium.
To search for further differences in the SPARC mRNA
expression between the different stages of Barrett’s progressive
disease, we compared the median SPARC expression of metaplastic
oesophagus (IM) tissues from patients with the maximum
diagnosis of BE (BE group) with dysplastic Barrett’s tissues from
patients with adenocarcinoma of the oesophagus (EA group). As
shown in Figure 3, the median SPARC expression was significantly
lower in Barrett’s IM (n¼16; median 3.16, range 0.21–7.19)
compared to Barrett’s dysplasia (n¼15; median 8.69; range 0.34–
53.62; P¼0.014; Mann–Whitney test).
Overall, the three groups of NE tissue revealed substantial
differences in SPARC expression levels (P¼0.03, Kruskal–Wallis
test). The median SPARC mRNA expression in the group of
histologically normal squamous oesophagus tissues from patients
with adenocarcinoma (median 1.79; range 0.14–16.54) was
significantly higher than the median SPARC expression found in
normal squamous oesophagus tissues from patients with BE only
(median 1.07; range 0.30–2.94; P¼0.04; Mann–Whitney test) and
normal squamous oesophagus tissues obtained from the CG
(median 0.58; range 0.45–1.17; P¼0.02; Mann–Whitney test;
Figure 4).
DISCUSSION
The main risk factor for the development of oesophageal
adenocarcinoma is the presence of BE. The mechanisms under-
lying the increased cancer development in this tissue are not fully
understood, but substantial evidence exists that progression to
Barrett’s cancer is associated with a variety of genetic and
epigenetic alterations (Rabinovitch et al, 1989; Reid et al, 1996;
Schneider et al, 1996). This study demonstrates that SPARC mRNA
expression is upregulated in BE and EAs. SPARC expression was
increased even in Barrett’s IM tissues, indicating that the induction
of the expression of this gene is an early event in the Barrett’s
adenocarcinoma progression. There was considerable variation of
SPARC mRNA expression levels in tissues at each Barrett’s stage,
but the analysis of grouped results showed that there was a
significant progressive elevation of SPARC expression through the
stages of Barrett’s IM to adenocarcinoma of the oesophagus. Our
findings complement the results of previous studies that reported
alterations in SPARC expression in various human cancers. The
overexpression of SPARC has been detected in melanoma (Ledda
et al, 1997a), colorectal cancer (Porte et al, 1995), breast cancer
(Bellahcene and Castronovo, 1995), hepatocellular carcinoma (Le
Bail et al, 1999), invasive meningiomas (Rempel et al, 1999), and
prostate cancer (Thomas et al, 2000). Moreover, it has been
reported that SPARC promotes cell migration and invasion in
prostate cancer (Jacob et al, 1999) and glioblastoma (Golembieski
et al, 1999). The suppression of SPARC expression by antisense
RNA results in a significant decrease in the tumorigenicity of
melanoma cells (Ledda et al, 1997b). These results suggest that
inappropriate SPARC expression is a somewhat specific effect that
contributes to tumour development and is not simply a function of
generalised inflammation in BE.
Our results suggest that quantitation of SPARC mRNA
expression offers promise as a biomarker for following disease
progression in individuals with BE. It seems plausible that BE
patients with a more abnormal SPARC expression profile are at
greater of progression to higher disease stages due to increased
capacity for invasion and proliferation, but this needs to be
demonstrated in studies of sequential biopsies in individual
patients. It is likely that molecular diagnosis and staging of BE
will probably require the assessment of a panel of gene
Table 2 SPARC mRNA expression in tissues from patients with adenocarcinoma and BE
SPARC expression
Pathology n Median Range Interquartile range (25th–75th percentiles) P-value
EA group 20
Adenocarcinoma 13.79 1.8–105.2 7.79–37.18 o0.001
BE 6.91 0.1–53.62 3.67–13.69
NE 1.79 0.1–16.5 0.59–3.05
BE group 19
BE 2.99 0.09–7.19 0.99–4.97 0.004
NE 1.07 0.29–2.94 0.42–1.52
CG group 10
NE 0.58 0.45–1.17 0.51–0.63
EA¼adenocarcinoma group; BE¼Barrett’s oesophagus group; CG¼control group.
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Figure 2 Box and whisker plots of relative SPARC mRNA expression
levels for NE, BE, and EA tissues from patients with EA of the oesophagus.
NE vs BE, P¼0.001; NE vs EA Po0.001; BE vs NE, P¼0.004.
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yexpressions. Studies from this institution and elsewhere suggest
that many genes have significantly different expressions or
mutation frequencies at different Barrett’s stages (Schneider et al,
1996; Eads et al, 2000; Lord et al, 2000, 2001; Brabender et al,
2001a,b, 2002)
The mechanism leading to inappropriate SPARC expression in
tumorigenesis, and whether the effects of SPARC on invasion and
proliferation are induced by mechanisms that are linked or
mutually exclusive is not yet known, and was not purpose of this
investigation. Further studies are warranted to determine the
underlying mechanisms leading to altered SPARC expression in
this disease.
SPARC mRNA expression levels were significantly higher in
normal squamous oesophagus tissues from patients with cancer
compared to patients with the maximum diagnosis of BE and the
CG without the evidence of BE or chronic gastro-oesophageal
reflux. We and others have found similar evidence for the
presence of a widespread oncogenic ‘field effect’ in the NE of
cancer patients in studies of gene expression and DNA methylation
analysis (Eads et al, 2000; Lord et al, 2000; Brabender et al,
2001a,b, 2002). One explanation for this field change is that
due to an injurious environmental agent, for example, the
gastro-oesophageal refluxate, some of the early events of
tumorigenesis have already occurred. These early events might
predispose the apparently normal squamous oesophagus tissue to
undergo further genetic changes leading ultimately to the
development of BE and adenocarcinoma. An alternative explana-
tion is that clones of abnormal cells, in the presence of cancer,
have expanded widely throughout the mucosa to replace
previously normal cells. In either case, it is apparent that genetic
changes can precede the appearance of morphologic changes in
this disease.
In summary, these data suggest that upregulation of SPARC
mRNA expression is an early event in Barrett’s multistage disease,
which already occurs at the level of IM and further increases
during progression to cancer. The presence of oesophageal
adenocarcinoma seems associated with an ‘oncogenic’ field effect
on the normal squamous oesophagus mucosa. Quantitation of
SPARC mRNA expression might be a novel biomarker for the
detection of cancer in patients with BE.
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